Expression of a novel androgen-regulated long noncoding RNA correlates with progression-free survival in prostate cancer patients

2016 ◽  
Author(s):  
Annika Kohvakka ◽  
Kati Kivinummi ◽  
Ville Kytola ◽  
Antti Ylipaa ◽  
Matti Annala ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Cancer Patients ◽  
Long Noncoding Rna ◽  
Noncoding Rna ◽  
Progression Free Survival ◽  
Free Survival

scholarly journals PVT1 Expression Is a Predictor for Poor Survival of Prostate Cancer Patients

2021 ◽  
Vol 20 ◽  
pp. 153303382097161
Author(s):  
Jianhua Liu ◽  
Yanqing Li ◽  
Qiqi Zhang ◽  
Chaoxiang Lv ◽  
Mingwei Wang ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Cancer Patients ◽  
Gleason Score ◽  
Roc Curve ◽  
Long Noncoding Rna ◽  
Noncoding Rna ◽  
Cox Regression ◽  
Molecular Therapy ◽  
Vital Status ◽  
Cox Regression Analysis

Objective: Dysregulation of long noncoding RNA is associated with a variety of cancers and LncRNA has anticancer or carcinogenic activities. PVT1, as a long noncoding RNA, plays an important role in the development of cancer. Methods: We use R to download and analyze the data in TCGA database. ROC curve is generated to evaluate the significance of PVT1 expression for the diagnosis of prostate cancer. Chi-square test is used to test correlation between PVT1 expression and clinical pathological features. Survival curve and univariate and multivariate cox regression analysis is performed to compare differences in the effect on the survival rate between PVT1 high expression and low expression. Results: The expression of PTV1 in tumor tissues was significantly higher than that in normal tissues(P<2.2e-16). The difference of PTV1 expression was observed according to vital status (P = 0.0051) and Gleason score (P = 0.0012). The expression of PTV1 is significantly associated with T classification (P < 0.0001), N classification (P = 0.0499), PSA (P = 0.0001), Gleason Score (P < 0.0001), targeted molecular therapy (P = 0.0264) and vital status(P = 0.0036). The area under the ROC curve (AUC) was 0.860, which revealed PTV1 expression has excellent diagnostic value in prostate cancer. Patients with high PVT1 expression had a worse prognosis. Conclusions: PVT1 expression may be a biomarker for the diagnosis and prognosis of prostate cancer.

scholarly journals Radical prostatectomy vs radiotherapy in high-risk prostate cancer patients: two centre experience

2015 ◽  
Vol 13 (4) ◽  
pp. 234-243
Author(s):  
Albertas Ulys ◽  
Agne Ulyte ◽  
Pavel Dziameshka ◽  
Oleg Sukonko ◽  
Sergei Krasny ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
High Risk ◽  
Cancer Patients ◽  
Gleason Score ◽  
Independent Predictor ◽  
Progression Free Survival ◽  
Free Survival ◽  
T Stage ◽  
High Risk Prostate Cancer ◽  
Risk Prostate Cancer

Background/objectiveThere are no randomized trials on the comparative effectiveness of radical prostatectomy (RP) and radiotherapy (RT) for high-risk prostate cancer. Our aim was to compare treatment outcomes of high-risk prostate cancer after RP and RT, including overall survival (OS), biochemical-progression-free survival (bPFS) and disease-progression-free survival (dPFS), using two cancer treatments centers’ patient data.MethodsData on high-risk prostate cancer patients between 2005 and 2009 were retrospectively reviewed in two cancer centers: National Cancer Institute, Vilnius, Lithuania and N.N. Alexandrov National Cancer Centre of Belarus, Minsk, Belarus; 210 patients were included in the study group treated with RP (n = 174) or RT (n = 36). The mean follow-up time was 5.6 and 6.6 years, respectively.ResultsLower T stage was an independent predictor of better OS (p = 0.01) and bPFS (p = 0.03). Only the highest Gleason score ≥8 was significantly predictive of a worse OS (p = 0.05), bPFS (p = 0.02) and dPFS (p = 0.001). A high PSA level was predictive of a worse bPFS (p = 0.007 for PSA ≥20) and dPFS (p = 0.008 for ≥20). The treatment modality in this study was insignificant after T stage, Gleason score and PSA level adjustment for OS, bPFS survival and dPFS survival (p = 0.17, p = 0.39, p = 0.20).ConclusionsThe T stage, Gleason score and pretreatment PSA level are significant factors for OS, bPFS survival, and dPFS survival of highrisk prostate cancer patients. Treatment option (RP or RT) was not an independent predictor of survival in this study.

scholarly journals An external validation of the Candiolo nomogram in a cohort of prostate cancer patients treated by external-beam radiotherapy

2021 ◽  
Author(s):  
Domenico Gabriele ◽  
Alessia Guarneri ◽  
Sara Bartoncini ◽  
Fernando Munoz ◽  
Matteo Tamponi ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
High Risk ◽  
Cancer Patients ◽  
External Validation ◽  
Progression Free Survival ◽  
Low Risk ◽  
Clinical Progression ◽  
Free Survival ◽  
Number Of Patients ◽  
Very High

Abstract Backgroundthe aim of this study is to perform an external validation for the Candiolo nomogram, a predictive algorithm of biochemical and clinical recurrences in prostate cancer patients treated by radical Radiotherapy, published in 2016 on the journal “Radiation Oncology”.Methods561 patients, treated by Radiotherapy with curative intent between 2003 and 2012, were classified according to the five risk-classes of the Candiolo nomogram and the three risk-classes of the D’Amico classification for comparison. Patients were treated with a mean prostatic dose of 77.7 Gy and a combined treatment with Androgen-Deprivation-Therapy in 76% of cases. The end-points of the study were biochemical-Progression-Free-Survival (bPFS) and clinical-Progression-Free-Survival (cPFS). With a median follow-up of 50 months, 56 patients (10%) had a biochemical relapse, and 30 patients (5.4%) a clinical progression. The cases were divided according to D’Amico in low-risk 21%, intermediate 40%, high-risk 39%; according to Candiolo very-low-risk 24%, low 37%, intermediate 24%, high 10%, very-high-risk 5%. Statistically, the Kaplan-Meier survival curves were processed and compared using Log-Rank tests and Harrell-C concordance index.ResultsThe 5-year bPFS for the Candiolo risk-classes range between 98% and 38%, and the 5-year cPFS between 98% and 50% for very-low and very-high-risk, respectively. The Candiolo nomogram is highly significant for the stratification of both bPFS and cPFS (P < 0.0001), as well as the D’Amico classification (P = 0.004 and P = 0.001, respectively). For the Candiolo nomogram, the C indexes for bPFS and cPFS are 75% and 80%, respectively, while for D'Amico classification they are 64% and 69%, respectively. The Candiolo nomogram can identify a greater number of patients with low and very-low-risk prostate cancer (61% versus 21% according to D'Amico) and it better picks out patients with high and very-high-risk of recurrence, equal to only 15% of the total cases but subject to 48% (27/56) of biochemical relapses and 63% (19/30) of clinical progressions.Conclusionsthe external validation of the Candiolo nomogram was overall successful with C indexes approximately 10% higher than the D'Amico control classification for bPFS and cPFS. Therefore, its clinical use is justified in prostate cancer patients before radical Radiotherapy.Trial registrationretrospectively registered.

scholarly journals Exosomal Long Noncoding RNA HOXD-AS1 Promotes Prostate Cancer Metastasis via miR-361-5p/FOXM1 Axis

2021 ◽  
Author(s):  
Yongming Jiang ◽  
Hui Zhao ◽  
Yuxiao Chen ◽  
Kangjian Li ◽  
Jianheng Chen ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Distant Metastasis ◽  
Long Noncoding Rna ◽  
Noncoding Rna ◽  
Cancer Metastasis ◽  
Specific Antigen ◽  
Luciferase Assay ◽  
Castration Resistant Prostate Cancer ◽  
Free Survival

Abstract Background: Development of distant metastasis is the main cause of deaths in prostate cancer (PCa) patients. Understanding the mechanism of PCa metastasis is of utmost importance to improve its prognosis. The role of exosomal long noncoding RNA (lncRNA) has been reported yet fully understood in the metastasis of PCa. Methods: Co-culture assay, in-situ hybridization and quantitative PCR (qPCR) were applied to identify the presence of HOXD-AS1 overexpressing exosomes secreted by of castration resistant prostate cancer (CRPC) cells. Migration and wound healing assays were carried out to evaluate the biological function of exosomal HOXD-AS1. Then a mouse model was used to elucidate the effect of exosomal HOXD-AS1 on distant metastasis of PCa in vivo. Further RNA immunoprecipitation and luciferase assay were applied to identify the interaction between HOXD-AS1 and miR-361-5p. Moreover, rescue experiment was conducted to prove the binding of exosomal HOXD-AS1 and miR-361-5p. Last but not least, the application of serum exosomal HOXD-AS1 as a diagnostic and prognostic biomarker for PCa was evaluated. Results: We discovered the exosomal lncRNA HOXD-AS1 is upregulated in CRPC cell line derived exosomes and serum exosomes from metastatic PCa patients, which correlated with its tissue expression. Further investigation confirmed exosomal HOXD-AS1 promotes prostate cancer cell metastasis in vitro and in vivo by inducing metastasis associated phenotype. Mechanistically exosomal HOXD-AS1 was internalized directly by PCa cells, acting as competing endogenous RNA (ceRNA) to modulate the miR-361-5p/FOXM1 axis, therefore promoting PCa metastasis. In addition, we found that serum exosomal HOXD-AS1 was upregulated in metastatic PCa patients, especially those with high volume disease. And it is correlated closely with Gleason Score, distant and nodal metastasis, Prostatic specific antigen (PSA) recurrence free survival and progression free survival (PFS). Conclusions: Our study sheds a new insight into the regulation of PCa distant metastasis by exosomal HOXD-AS1 mediated miR-361-5p/FOXM1 axis, and provided a promising liquid biopsy biomarker as well as therapeutic target to the detection and treatment of metastatic PCa.

Sign in / Sign up

Export Citation Format

Share Document